Clinical Trial

Lymphocyte to Procalcitonin Ratio in Covid-19 Patients

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-27.
Trial Details
NCT Number NCT06620159
Lead Sponsor Suleyman Demirel University
Conditions COVID-19
Enrollment 535 participants
Start Date 2020-04-01
Primary Completion 2024-09-27 (estimated)
Study Completion 2024-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-03